COVID-19

Pfizer and BioNTech expect to produce up to 50 million doses globally in 2020 and up to 1.3 billion doses by the end of 2021.

Officials with Operation Warp Speed said distribution of a COVID-19 vaccine will begin within 24 hours after FDA authorization.

Pfizer and BioNTech today announced that their COVID-19 vaccine candidate showed a 95% efficacy rate in the final analysis of its phase 3 study.

Moderna announced today that its messenger RNA vaccine candidate for COVID-19 met the primary endpoint of efficacy, according to the study’s first interim analysis.

Here’s a roundup of the latest coronavirus-related news.

As part of a new partnership with HHS, the nation’s largest pharmacy chains—as well as independents and regional chains—will be administering free coronavirus disease 2019 (COVID-19) vaccines when they are available.

The FDA has granted Fast Track Designation for NVX-CoV2373, a vaccine candidate for COVID-19.

The FDA has authorized Lilly’s investigational neutralizing antibody for COVID-19 treatment in the outpatient setting.

Interim analysis results from a phase 3 clinical trial reported a vaccine efficacy rate above 90% for BNT162b2. The trial is ongoing until it meets its threshold for confirmed COVID-19 cases.

Here's the coronavirus-related news from this week.

Guest host Brian Nightengale, president of Good Neighbor Pharmacy, is joined by Rich Tremonte and Doug Hoey to discuss the biggest opportunities and headwinds facing independent pharmacies in 2021.

MJH Life Sciences™ COVID-19 Coalition will be hosting its next live webinar event “Thinking Long-Term: COVID-19’s Clinical Consequences and Mental Health Effects."

Members of the MJH COVID-19 Coalition were surveyed about strategies for pandemic containment.

The UK study examined the cross-sectional association between vitamins A, E, C, and D and respiratory complaints.

Here’s a preview of the featured content to watch for this week on Drug Topics®.

The recent uptick in antibiotic use interrupted a steady 4-year downward trend, according to study authors.

Robert Hopkins, chair of the National Vaccine Advisory Committee, discusses the most pressing issues coming out of the recent NVAC meeting and pharmacy's role amid the COVID-19 pandemic.

Regeneron’s REGN-COV2 met primary and key secondary end points in its phase 2/3 trial evaluating the drug in the COVID-19 outpatient setting.

Robert Hopkins, chair of the National Vaccine Advisory Committee, discusses the most pressing issues coming out of the recent NVAC meeting, and pharmacy's role amid the COVID-19 pandemic.

CMS’ new plan will ensure coverage of COVID-19 vaccines with no out-of-pocket costs, while increasing the number of providers that will administer the vaccine.

Here's the coronavirus-related news from this week that you should know. 

For our first episode in the ThoughtSpot 2020 series, experts from AmerisourceBergen and Healthcare Ready discuss how to support marginalized communities amid pandemics and natural disasters.

Although the company has ended the ACTIV-3 clinical trial, researchers are continuing to pursue all other studies of bamlanivimab in COVID-19.

Investigators stressed that governments, public health officials, and other non-governmental organizations should aim to build trust in a COVID-19 vaccine.

Here's the coronavirus-related news from this week that you should know.